Premium
Mitochondrial pharmacology: Electron transport chain bypass as strategies to treat mitochondrial dysfunction
Author(s) -
Atamna Hani,
Mackey Jeanette,
Dhahbi Joseph M.
Publication year - 2012
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.197
Subject(s) - redox , mitochondrion , cytosol , reactive oxygen species , electron transport chain , microbiology and biotechnology , biology , mitochondrial ros , biochemistry , chemistry , enzyme , organic chemistry
Abstract Mitochondrial dysfunction (primary or secondary) is detrimental to intermediary metabolism. Therapeutic strategies to treat/prevent mitochondrial dysfunction could be valuable for managing metabolic and age‐related disorders. Here, we review strategies proposed to treat mitochondrial impairment. We then concentrate on redox‐active agents, with mild‐redox potential, who shuttle electrons among specific cytosolic or mitochondrial redox‐centers. We propose that specific redox agents with mild redox potential (−0.1 V; 0.1 V) improve mitochondrial function because they can readily donate or accept electrons in biological systems, thus they enhance metabolic activity and prevent reactive oxygen species (ROS) production. These agents are likely to lack toxic effects because they lack the risk of inhibiting electron transfer in redox centers. This is different from redox agents with strong negative (−0.4 V; −0.2 V) or positive (0.2 V; 0.4 V) redox potentials who alter the redox status of redox‐centers ( i.e., become permanently reduced or oxidized). This view has been demonstrated by testing the effect of several redox active agents on cellular senescence. Methylene blue (MB, redox potential ≅10 mV) appears to readily cycle between the oxidized and reduced forms using specific mitochondrial and cytosolic redox centers. MB is most effective in delaying cell senescence and enhancing mitochondrial function in vivo and in vitro . Mild‐redox agents can alter the biochemical activity of specific mitochondrial components, which then in response alters the expression of nuclear and mitochondrial genes. We present the concept of mitochondrial electron‐carrier bypass as a potential result of mild‐redox agents, a method to prevent ROS production, improve mitochondrial function, and delay cellular aging. Thus, mild‐redox agents may prevent/delay mitochondria‐driven disorders.